APO Research
Talk to an analyst

APO RESEARCH · REPORT

Live Attenuated Measles Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Live Attenuated Measles Vaccine Market Analysis and Forecast 2026-2032

30 December 2025204 pages

Choose your research edition.

Industry ResearchLive Attenuated Measles Vaccine Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Live Attenuated Measles Vaccine Industry Growth and Trends Forecast to 2032118 pages · $3,450 USDMarket StructureGlobal Live Attenuated Measles Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Live Attenuated Measles Vaccine Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Live Attenuated Measles Vaccine Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Live Attenuated Measles Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Live Attenuated Measles Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Live Attenuated Measles Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Live Attenuated Measles Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Live Attenuated Measles Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Live Attenuated Measles Vaccine include GSK, Bavarian Nordic, CSL Limited, Emergent Biosolutions, Medimmune, Sanofi-Pasteur, Serum Institute of India, Beijing Institute of Biological Products Co., Ltd and Pfizer, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Live Attenuated Measles Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Live Attenuated Measles Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Live Attenuated Measles Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Live Attenuated Measles Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Live Attenuated Measles Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Live Attenuated Measles Vaccine sales, projected growth trends, production technology, application and end-user industry.

Live Attenuated Measles Vaccine Segment by Company

GSK

Bavarian Nordic

CSL Limited

Emergent Biosolutions

Medimmune

Sanofi-Pasteur

Serum Institute of India

Beijing Institute of Biological Products Co., Ltd

Pfizer

Lanzhou Institute of Biological Products Co., Ltd

Merck

Novartis

Johnson & Johnson

Shanghai Institute of Biological Products Co., Ltd

Wuhan Institute of Biological Products Co., Ltd

Changchun Qijian Biological Products Co., Ltd

Live Attenuated Measles Vaccine Segment by Type

Liquid

Powder

Live Attenuated Measles Vaccine Segment by Application

Hospital

Clinic

Live Attenuated Measles Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Attenuated Measles Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Live Attenuated Measles Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Attenuated Measles Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Live Attenuated Measles Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Live Attenuated Measles Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Live Attenuated Measles Vaccine sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Live Attenuated Measles Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Liquid Major Manufacturers Table 3. Powder Major Manufacturers Table 4. Global Live Attenuated Measles Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Manufacturers Table 6. Clinic Major Manufacturers Table 7. Live Attenuated Measles Vaccine Industry Trends Table 8. Live Attenuated Measles Vaccine Industry Drivers Table 9. Live Attenuated Measles Vaccine Industry Opportunities and Challenges Table 10. Live Attenuated Measles Vaccine Industry Restraints Table 11. Global Live Attenuated Measles Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 12. Global Live Attenuated Measles Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 13. Global Live Attenuated Measles Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 14. Global Live Attenuated Measles Vaccine Revenue Market Share by Region (2021-2026) Table 15. Global Live Attenuated Measles Vaccine Revenue Market Share by Region (2027-2032) Table 16. Global Live Attenuated Measles Vaccine Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 17. Global Live Attenuated Measles Vaccine Sales by Region (2021-2026) & (K Units) Table 18. Global Live Attenuated Measles Vaccine Sales by Region (2027-2032) & (K Units) Table 19. Global Live Attenuated Measles Vaccine Sales Market Share by Region (2021-2026) Table 20. Global Live Attenuated Measles Vaccine Sales Market Share by Region (2027-2032) Table 21. Global Live Attenuated Measles Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 22. Global Live Attenuated Measles Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 23. Global Live Attenuated Measles Vaccine Sales by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Live Attenuated Measles Vaccine Sales Market Share by Manufacturers (2021-2026) Table 25. Global Live Attenuated Measles Vaccine Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 26. Global Live Attenuated Measles Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 27. Global Live Attenuated Measles Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 28. Global Live Attenuated Measles Vaccine Manufacturers, Product Type & Application Table 29. Global Live Attenuated Measles Vaccine Manufacturers' Establishment Date Table 30. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 31. Global Live Attenuated Measles Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 32. Global Live Attenuated Measles Vaccine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Live Attenuated Measles Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 34. Global Live Attenuated Measles Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 35. Global Live Attenuated Measles Vaccine Revenue Market Share by Type (2021-2026) Table 36. Global Live Attenuated Measles Vaccine Revenue Market Share by Type (2027-2032) Table 37. Global Live Attenuated Measles Vaccine Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 38. Global Live Attenuated Measles Vaccine Sales by Type (2021-2026) & (K Units) Table 39. Global Live Attenuated Measles Vaccine Sales by Type (2027-2032) & (K Units) Table 40. Global Live Attenuated Measles Vaccine Sales Market Share by Type (2021-2026) Table 41. Global Live Attenuated Measles Vaccine Sales Market Share by Type (2027-2032) Table 42. Global Live Attenuated Measles Vaccine Price by Type (2021-2026) & (US$/Unit) Table 43. Global Live Attenuated Measles Vaccine Price by Type (2027-2032) & (US$/Unit) Table 44. Global Live Attenuated Measles Vaccine Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 45. Global Live Attenuated Measles Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 46. Global Live Attenuated Measles Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 47. Global Live Attenuated Measles Vaccine Revenue Market Share by Application (2021-2026) Table 48. Global Live Attenuated Measles Vaccine Revenue Market Share by Application (2027-2032) Table 49. Global Live Attenuated Measles Vaccine Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 50. Global Live Attenuated Measles Vaccine Sales by Application (2021-2026) & (K Units) Table 51. Global Live Attenuated Measles Vaccine Sales by Application (2027-2032) & (K Units) Table 52. Global Live Attenuated Measles Vaccine Sales Market Share by Application (2021-2026) Table 53. Global Live Attenuated Measles Vaccine Sales Market Share by Application (2027-2032) Table 54. Global Live Attenuated Measles Vaccine Price by Application (2021-2026) & (US$/Unit) Table 55. Global Live Attenuated Measles Vaccine Price by Application (2027-2032) & (US$/Unit) Table 56. GSK Company Information Table 57. GSK Business Overview Table 58. GSK Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 59. GSK Live Attenuated Measles Vaccine Product Portfolio Table 60. GSK Recent Development Table 61. Bavarian Nordic Company Information Table 62. Bavarian Nordic Business Overview Table 63. Bavarian Nordic Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 64. Bavarian Nordic Live Attenuated Measles Vaccine Product Portfolio Table 65. Bavarian Nordic Recent Development Table 66. CSL Limited Company Information Table 67. CSL Limited Business Overview Table 68. CSL Limited Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. CSL Limited Live Attenuated Measles Vaccine Product Portfolio Table 70. CSL Limited Recent Development Table 71. Emergent Biosolutions Company Information Table 72. Emergent Biosolutions Business Overview Table 73. Emergent Biosolutions Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Emergent Biosolutions Live Attenuated Measles Vaccine Product Portfolio Table 75. Emergent Biosolutions Recent Development Table 76. Medimmune Company Information Table 77. Medimmune Business Overview Table 78. Medimmune Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Medimmune Live Attenuated Measles Vaccine Product Portfolio Table 80. Medimmune Recent Development Table 81. Sanofi-Pasteur Company Information Table 82. Sanofi-Pasteur Business Overview Table 83. Sanofi-Pasteur Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Sanofi-Pasteur Live Attenuated Measles Vaccine Product Portfolio Table 85. Sanofi-Pasteur Recent Development Table 86. Serum Institute of India Company Information Table 87. Serum Institute of India Business Overview Table 88. Serum Institute of India Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Serum Institute of India Live Attenuated Measles Vaccine Product Portfolio Table 90. Serum Institute of India Recent Development Table 91. Beijing Institute of Biological Products Co., Ltd Company Information Table 92. Beijing Institute of Biological Products Co., Ltd Business Overview Table 93. Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio Table 95. Beijing Institute of Biological Products Co., Ltd Recent Development Table 96. Pfizer Company Information Table 97. Pfizer Business Overview Table 98. Pfizer Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Pfizer Live Attenuated Measles Vaccine Product Portfolio Table 100. Pfizer Recent Development Table 101. Lanzhou Institute of Biological Products Co., Ltd Company Information Table 102. Lanzhou Institute of Biological Products Co., Ltd Business Overview Table 103. Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio Table 105. Lanzhou Institute of Biological Products Co., Ltd Recent Development Table 106. Merck Company Information Table 107. Merck Business Overview Table 108. Merck Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Merck Live Attenuated Measles Vaccine Product Portfolio Table 110. Merck Recent Development Table 111. Novartis Company Information Table 112. Novartis Business Overview Table 113. Novartis Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Novartis Live Attenuated Measles Vaccine Product Portfolio Table 115. Novartis Recent Development Table 116. Johnson & Johnson Company Information Table 117. Johnson & Johnson Business Overview Table 118. Johnson & Johnson Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Johnson & Johnson Live Attenuated Measles Vaccine Product Portfolio Table 120. Johnson & Johnson Recent Development Table 121. Shanghai Institute of Biological Products Co., Ltd Company Information Table 122. Shanghai Institute of Biological Products Co., Ltd Business Overview Table 123. Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio Table 125. Shanghai Institute of Biological Products Co., Ltd Recent Development Table 126. Wuhan Institute of Biological Products Co., Ltd Company Information Table 127. Wuhan Institute of Biological Products Co., Ltd Business Overview Table 128. Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio Table 130. Wuhan Institute of Biological Products Co., Ltd Recent Development Table 131. Changchun Qijian Biological Products Co., Ltd Company Information Table 132. Changchun Qijian Biological Products Co., Ltd Business Overview Table 133. Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio Table 135. Changchun Qijian Biological Products Co., Ltd Recent Development Table 136. North America Live Attenuated Measles Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 137. North America Live Attenuated Measles Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 138. North America Live Attenuated Measles Vaccine Sales by Type (2021-2026) & (K Units) Table 139. North America Live Attenuated Measles Vaccine Sales by Type (2027-2032) & (K Units) Table 140. North America Live Attenuated Measles Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 141. North America Live Attenuated Measles Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 142. North America Live Attenuated Measles Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 143. North America Live Attenuated Measles Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 144. North America Live Attenuated Measles Vaccine Sales by Application (2021-2026) & (K Units) Table 145. North America Live Attenuated Measles Vaccine Sales by Application (2027-2032) & (K Units) Table 146. North America Live Attenuated Measles Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 147. North America Live Attenuated Measles Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 148. North America Live Attenuated Measles Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 149. North America Live Attenuated Measles Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 150. North America Live Attenuated Measles Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 151. North America Live Attenuated Measles Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 152. North America Live Attenuated Measles Vaccine Sales by Country (2021-2026) & (K Units) Table 153. North America Live Attenuated Measles Vaccine Sales by Country (2027-2032) & (K Units) Table 154. North America Live Attenuated Measles Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 155. North America Live Attenuated Measles Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 156. United States Live Attenuated Measles Vaccine Revenue (2021-2032) & (US$ Million) Table 157. Canada Live Attenuated Measles Vaccine Revenue (2021-2032) & (US$ Million) Table 158. Europe Live Attenuated Measles Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 159. Europe Live Attenuated Measles Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 160. Europe Live Attenuated Measles Vaccine Sales by Type (2021-2026) & (K Units) Table 161. Europe Live Attenuated Measles Vaccine Sales by Type (2027-2032) & (K Units) Table 162. Europe Live Attenuated Measles Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 163. Europe Live Attenuated Measles Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 164. Europe Live Attenuated Measles Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 165. Europe Live Attenuated Measles Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 166. Europe Live Attenuated Measles Vaccine Sales by Application (2021-2026) & (K Units) Table 167. Europe Live Attenuated Measles Vaccine Sales by Application (2027-2032) & (K Units) Table 168. Europe Live Attenuated Measles Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 169. Europe Live Attenuated Measles Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 170. Europe Live Attenuated Measles Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 171. Europe Live Attenuated Measles Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 172. Europe Live Attenuated Measles Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 173. Europe Live Attenuated Measles Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 174. Europe Live Attenuated Measles Vaccine Sales by Country (2021-2026) & (K Units) Table 175. Europe Live Attenuated Measles Vaccine Sales by Country (2027-2032) & (K Units) Table 176. Europe Live Attenuated Measles Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 177. Europe Live Attenuated Measles Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 178. Germany Live Attenuated Measles Vaccine Revenue (2021-2032) & (US$ Million) Table 179. France Live Attenuated Measles Vaccine Revenue (2021-2032) & (US$ Million) Table 180. U.K. Live Attenuated Measles Vaccine Revenue (2021-2032) & (US$ Million) Table 181. Italy Live Attenuated Measles Vaccine Revenue (2021-2032) & (US$ Million) Table 182. Netherlands Live Attenuated Measles Vaccine Revenue (2021-2032) & (US$ Million) Table 183. China Live Attenuated Measles Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 184. China Live Attenuated Measles Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 185. China Live Attenuated Measles Vaccine Sales by Type (2021-2026) & (K Units) Table 186. China Live Attenuated Measles Vaccine Sales by Type (2027-2032) & (K Units) Table 187. China Live Attenuated Measles Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 188. China Live Attenuated Measles Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 189. China Live Attenuated Measles Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 190. China Live Attenuated Measles Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 191. China Live Attenuated Measles Vaccine Sales by Application (2021-2026) & (K Units) Table 192. China Live Attenuated Measles Vaccine Sales by Application (2027-2032) & (K Units) Table 193. China Live Attenuated Measles Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 194. China Live Attenuated Measles Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 195. Asia Live Attenuated Measles Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 196. Asia Live Attenuated Measles Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 197. Asia Live Attenuated Measles Vaccine Sales by Type (2021-2026) & (K Units) Table 198. Asia Live Attenuated Measles Vaccine Sales by Type (2027-2032) & (K Units) Table 199. Asia Live Attenuated Measles Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 200. Asia Live Attenuated Measles Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 201. Asia Live Attenuated Measles Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 202. Asia Live Attenuated Measles Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 203. Asia Live Attenuated Measles Vaccine Sales by Application (2021-2026) & (K Units) Table 204. Asia Live Attenuated Measles Vaccine Sales by Application (2027-2032) & (K Units) Table 205. Asia Live Attenuated Measles Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 206. Asia Live Attenuated Measles Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 207. Asia Live Attenuated Measles Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 208. Asia Live Attenuated Measles Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 209. Asia Live Attenuated Measles Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 210. Asia Live Attenuated Measles Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 211. Asia Live Attenuated Measles Vaccine Sales by Country (2021-2026) & (K Units) Table 212. Asia Live Attenuated Measles Vaccine Sales by Country (2027-2032) & (K Units) Table 213. Asia Live Attenuated Measles Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 214. Asia Live Attenuated Measles Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 215. Japan Live Attenuated Measles Vaccine Revenue (2021-2032) & (US$ Million) Table 216. South Korea Live Attenuated Measles Vaccine Revenue (2021-2032) & (US$ Million) Table 217. India Live Attenuated Measles Vaccine Revenue (2021-2032) & (US$ Million) Table 218. Australia Live Attenuated Measles Vaccine Revenue (2021-2032) & (US$ Million) Table 219. China Taiwan Live Attenuated Measles Vaccine Revenue (2021-2032) & (US$ Million) Table 220. Southeast Asia Live Attenuated Measles Vaccine Revenue (2021-2032) & (US$ Million) Table 221. SAMEA Live Attenuated Measles Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 222. SAMEA Live Attenuated Measles Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 223. SAMEA Live Attenuated Measles Vaccine Sales by Type (2021-2026) & (K Units) Table 224. SAMEA Live Attenuated Measles Vaccine Sales by Type (2027-2032) & (K Units) Table 225. SAMEA Live Attenuated Measles Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 226. SAMEA Live Attenuated Measles Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 227. SAMEA Live Attenuated Measles Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 228. SAMEA Live Attenuated Measles Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 229. SAMEA Live Attenuated Measles Vaccine Sales by Application (2021-2026) & (K Units) Table 230. SAMEA Live Attenuated Measles Vaccine Sales by Application (2027-2032) & (K Units) Table 231. SAMEA Live Attenuated Measles Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 232. SAMEA Live Attenuated Measles Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 233. SAMEA Live Attenuated Measles Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 234. SAMEA Live Attenuated Measles Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 235. SAMEA Live Attenuated Measles Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 236. SAMEA Live Attenuated Measles Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 237. SAMEA Live Attenuated Measles Vaccine Sales by Country (2021-2026) & (K Units) Table 238. SAMEA Live Attenuated Measles Vaccine Sales by Country (2027-2032) & (K Units) Table 239. SAMEA Live Attenuated Measles Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 240. SAMEA Live Attenuated Measles Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 241. Brazil Live Attenuated Measles Vaccine Revenue (2021-2032) & (US$ Million) Table 242. Argentina Live Attenuated Measles Vaccine Revenue (2021-2032) & (US$ Million) Table 243. Chile Live Attenuated Measles Vaccine Revenue (2021-2032) & (US$ Million) Table 244. Colombia Live Attenuated Measles Vaccine Revenue (2021-2032) & (US$ Million) Table 245. Peru Live Attenuated Measles Vaccine Revenue (2021-2032) & (US$ Million) Table 246. Saudi Arabia Live Attenuated Measles Vaccine Revenue (2021-2032) & (US$ Million) Table 247. Israel Live Attenuated Measles Vaccine Revenue (2021-2032) & (US$ Million) Table 248. UAE Live Attenuated Measles Vaccine Revenue (2021-2032) & (US$ Million) Table 249. Turkey Live Attenuated Measles Vaccine Revenue (2021-2032) & (US$ Million) Table 250. Iran Live Attenuated Measles Vaccine Revenue (2021-2032) & (US$ Million) Table 251. Egypt Live Attenuated Measles Vaccine Revenue (2021-2032) & (US$ Million) Table 252. Key Raw Materials Table 253. Raw Materials Key Suppliers Table 254. Live Attenuated Measles Vaccine Distributors List Table 255. Live Attenuated Measles Vaccine Customers List Table 256. Research Programs/Design for This Report Table 257. Authors List of This Report Table 258. Secondary Sources Table 259. Primary Sources List of Figures Figure 1. Live Attenuated Measles Vaccine Image Figure 2. Global Live Attenuated Measles Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Live Attenuated Measles Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 4. Liquid Image Figure 5. Powder Image Figure 6. Global Live Attenuated Measles Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Live Attenuated Measles Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Clinic Image Figure 10. Global Live Attenuated Measles Vaccine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Live Attenuated Measles Vaccine Revenue (2021-2032) & (US$ Million) Figure 12. Global Live Attenuated Measles Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 13. Global Live Attenuated Measles Vaccine Revenue Market Share by Region: 2025 Versus 2032 Figure 14. Global Live Attenuated Measles Vaccine Revenue Market Share by Region (2021-2032) Figure 15. Global Live Attenuated Measles Vaccine Sales (2021-2032) & (K Units) Figure 16. Global Live Attenuated Measles Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 17. Global Live Attenuated Measles Vaccine Sales Market Share by Region (2021-2032) Figure 18. US & Canada & Mexico Live Attenuated Measles Vaccine Sales YoY (2021-2032) & (K Units) Figure 19. Europe Live Attenuated Measles Vaccine Sales YoY (2021-2032) & (K Units) Figure 20. China Live Attenuated Measles Vaccine Sales YoY (2021-2032) & (K Units) Figure 21. Asia (Excluding China) Live Attenuated Measles Vaccine Sales YoY (2021-2032) & (K Units) Figure 22. South America, Middle East and Africa Live Attenuated Measles Vaccine Sales YoY (2021-2032) & (K Units) Figure 23. Global Live Attenuated Measles Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 24. Global Live Attenuated Measles Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 25. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 26. Global Live Attenuated Measles Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Live Attenuated Measles Vaccine Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 28. Global Live Attenuated Measles Vaccine Revenue Market Share by Type (2021-2032) Figure 29. Global Live Attenuated Measles Vaccine Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 30. Global Live Attenuated Measles Vaccine Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Live Attenuated Measles Vaccine Sales Market Share by Type (2021-2032) Figure 32. Global Live Attenuated Measles Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global Live Attenuated Measles Vaccine Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 34. Global Live Attenuated Measles Vaccine Revenue Market Share by Application (2021-2032) Figure 35. Global Live Attenuated Measles Vaccine Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 36. Global Live Attenuated Measles Vaccine Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Live Attenuated Measles Vaccine Sales Market Share by Application (2021-2032) Figure 38. North America Live Attenuated Measles Vaccine Revenue Share by Type (2021-2032) Figure 39. North America Live Attenuated Measles Vaccine Sales Share by Type (2021-2032) Figure 40. North America Live Attenuated Measles Vaccine Revenue Share by Application (2021-2032) Figure 41. North America Live Attenuated Measles Vaccine Sales Share by Application (2021-2032) Figure 42. North America Live Attenuated Measles Vaccine Revenue Share by Country (2021-2032) Figure 43. North America Live Attenuated Measles Vaccine Sales Share by Country (2021-2032) Figure 44. Europe Live Attenuated Measles Vaccine Revenue Share by Type (2021-2032) Figure 45. Europe Live Attenuated Measles Vaccine Sales Share by Type (2021-2032) Figure 46. Europe Live Attenuated Measles Vaccine Revenue Share by Application (2021-2032) Figure 47. Europe Live Attenuated Measles Vaccine Sales Share by Application (2021-2032) Figure 48. Europe Live Attenuated Measles Vaccine Revenue Share by Country (2021-2032) Figure 49. Europe Live Attenuated Measles Vaccine Sales Share by Country (2021-2032) Figure 50. China Live Attenuated Measles Vaccine Revenue Share by Type (2021-2032) Figure 51. China Live Attenuated Measles Vaccine Sales Share by Type (2021-2032) Figure 52. China Live Attenuated Measles Vaccine Revenue Share by Application (2021-2032) Figure 53. China Live Attenuated Measles Vaccine Sales Share by Application (2021-2032) Figure 54. Asia Live Attenuated Measles Vaccine Revenue Share by Type (2021-2032) Figure 55. Asia Live Attenuated Measles Vaccine Sales Share by Type (2021-2032) Figure 56. Asia Live Attenuated Measles Vaccine Revenue Share by Application (2021-2032) Figure 57. Asia Live Attenuated Measles Vaccine Sales Share by Application (2021-2032) Figure 58. Asia Live Attenuated Measles Vaccine Revenue Share by Country (2021-2032) Figure 59. Asia Live Attenuated Measles Vaccine Sales Share by Country (2021-2032) Figure 60. SAMEA Live Attenuated Measles Vaccine Revenue Share by Type (2021-2032) Figure 61. SAMEA Live Attenuated Measles Vaccine Sales Share by Type (2021-2032) Figure 62. SAMEA Live Attenuated Measles Vaccine Revenue Share by Application (2021-2032) Figure 63. SAMEA Live Attenuated Measles Vaccine Sales Share by Application (2021-2032) Figure 64. SAMEA Live Attenuated Measles Vaccine Revenue Share by Country (2021-2032) Figure 65. SAMEA Live Attenuated Measles Vaccine Sales Share by Country (2021-2032) Figure 66. Live Attenuated Measles Vaccine Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Live Attenuated Measles Vaccine Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Liquid
  • Powder
Applications
  • Hospital
  • Clinic
Companies covered
  • GSK
  • Bavarian Nordic
  • CSL Limited
  • Emergent Biosolutions
  • Medimmune
  • Sanofi-Pasteur
  • Serum Institute of India
  • Beijing Institute of Biological Products Co., Ltd
  • Pfizer
  • Lanzhou Institute of Biological Products Co., Ltd
  • Merck
  • Novartis
  • Johnson & Johnson
  • Shanghai Institute of Biological Products Co., Ltd
  • Wuhan Institute of Biological Products Co., Ltd
  • Changchun Qijian Biological Products Co., Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Live Attenuated Measles Vaccine Market by Type
  3. 1.2.1 Global Live Attenuated Measles Vaccine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Liquid
  5. 1.2.3 Powder
  6. 1.3 Live Attenuated Measles Vaccine Market by Application
  7. 1.3.1 Global Live Attenuated Measles Vaccine Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Clinic
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Live Attenuated Measles Vaccine Market Dynamics
  1. 2.1 Live Attenuated Measles Vaccine Industry Trends
  2. 2.2 Live Attenuated Measles Vaccine Industry Drivers
  3. 2.3 Live Attenuated Measles Vaccine Industry Opportunities and Challenges
  4. 2.4 Live Attenuated Measles Vaccine Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Live Attenuated Measles Vaccine Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Live Attenuated Measles Vaccine Revenue by Region
  3. 3.2.1 Global Live Attenuated Measles Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Live Attenuated Measles Vaccine Revenue by Region (2021-2026)
  5. 3.2.3 Global Live Attenuated Measles Vaccine Revenue by Region (2027-2032)
  6. 3.2.4 Global Live Attenuated Measles Vaccine Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Live Attenuated Measles Vaccine Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Live Attenuated Measles Vaccine Sales by Region
  9. 3.4.1 Global Live Attenuated Measles Vaccine Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Live Attenuated Measles Vaccine Sales by Region (2021-2026)
  11. 3.4.3 Global Live Attenuated Measles Vaccine Sales by Region (2027-2032)
  12. 3.4.4 Global Live Attenuated Measles Vaccine Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Live Attenuated Measles Vaccine Revenue by Manufacturers
  2. 4.1.1 Global Live Attenuated Measles Vaccine Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Live Attenuated Measles Vaccine Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Live Attenuated Measles Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Live Attenuated Measles Vaccine Sales by Manufacturers
  6. 4.2.1 Global Live Attenuated Measles Vaccine Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Live Attenuated Measles Vaccine Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Live Attenuated Measles Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Live Attenuated Measles Vaccine Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Live Attenuated Measles Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Live Attenuated Measles Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Live Attenuated Measles Vaccine Manufacturers, Product Type & Application
  13. 4.7 Global Live Attenuated Measles Vaccine Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Live Attenuated Measles Vaccine Market CR5 and HHI
  16. 4.8.2 2025 Live Attenuated Measles Vaccine Tier 1, Tier 2, and Tier 3
5 Live Attenuated Measles Vaccine Market by Type
  1. 5.1 Global Live Attenuated Measles Vaccine Revenue by Type
  2. 5.1.1 Global Live Attenuated Measles Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Live Attenuated Measles Vaccine Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Live Attenuated Measles Vaccine Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Live Attenuated Measles Vaccine Sales by Type
  6. 5.2.1 Global Live Attenuated Measles Vaccine Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Live Attenuated Measles Vaccine Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Live Attenuated Measles Vaccine Sales Market Share by Type (2021-2032)
  9. 5.3 Global Live Attenuated Measles Vaccine Price by Type
6 Live Attenuated Measles Vaccine Market by Application
  1. 6.1 Global Live Attenuated Measles Vaccine Revenue by Application
  2. 6.1.1 Global Live Attenuated Measles Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Live Attenuated Measles Vaccine Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Live Attenuated Measles Vaccine Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Live Attenuated Measles Vaccine Sales by Application
  6. 6.2.1 Global Live Attenuated Measles Vaccine Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Live Attenuated Measles Vaccine Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Live Attenuated Measles Vaccine Sales Market Share by Application (2021-2032)
  9. 6.3 Global Live Attenuated Measles Vaccine Price by Application
7 Company Profiles
  1. 7.1 GSK
  2. 7.1.1 GSK Company Information
  3. 7.1.2 GSK Business Overview
  4. 7.1.3 GSK Live Attenuated Measles Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 GSK Live Attenuated Measles Vaccine Product Portfolio
  6. 7.1.5 GSK Recent Developments
  7. 7.2 Bavarian Nordic
  8. 7.2.1 Bavarian Nordic Company Information
  9. 7.2.2 Bavarian Nordic Business Overview
  10. 7.2.3 Bavarian Nordic Live Attenuated Measles Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Bavarian Nordic Live Attenuated Measles Vaccine Product Portfolio
  12. 7.2.5 Bavarian Nordic Recent Developments
  13. 7.3 CSL Limited
  14. 7.3.1 CSL Limited Company Information
  15. 7.3.2 CSL Limited Business Overview
  16. 7.3.3 CSL Limited Live Attenuated Measles Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 CSL Limited Live Attenuated Measles Vaccine Product Portfolio
  18. 7.3.5 CSL Limited Recent Developments
  19. 7.4 Emergent Biosolutions
  20. 7.4.1 Emergent Biosolutions Company Information
  21. 7.4.2 Emergent Biosolutions Business Overview
  22. 7.4.3 Emergent Biosolutions Live Attenuated Measles Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Emergent Biosolutions Live Attenuated Measles Vaccine Product Portfolio
  24. 7.4.5 Emergent Biosolutions Recent Developments
  25. 7.5 Medimmune
  26. 7.5.1 Medimmune Company Information
  27. 7.5.2 Medimmune Business Overview
  28. 7.5.3 Medimmune Live Attenuated Measles Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Medimmune Live Attenuated Measles Vaccine Product Portfolio
  30. 7.5.5 Medimmune Recent Developments
  31. 7.6 Sanofi-Pasteur
  32. 7.6.1 Sanofi-Pasteur Company Information
  33. 7.6.2 Sanofi-Pasteur Business Overview
  34. 7.6.3 Sanofi-Pasteur Live Attenuated Measles Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Sanofi-Pasteur Live Attenuated Measles Vaccine Product Portfolio
  36. 7.6.5 Sanofi-Pasteur Recent Developments
  37. 7.7 Serum Institute of India
  38. 7.7.1 Serum Institute of India Company Information
  39. 7.7.2 Serum Institute of India Business Overview
  40. 7.7.3 Serum Institute of India Live Attenuated Measles Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Serum Institute of India Live Attenuated Measles Vaccine Product Portfolio
  42. 7.7.5 Serum Institute of India Recent Developments
  43. 7.8 Beijing Institute of Biological Products Co., Ltd
  44. 7.8.1 Beijing Institute of Biological Products Co., Ltd Company Information
  45. 7.8.2 Beijing Institute of Biological Products Co., Ltd Business Overview
  46. 7.8.3 Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
  48. 7.8.5 Beijing Institute of Biological Products Co., Ltd Recent Developments
  49. 7.9 Pfizer
  50. 7.9.1 Pfizer Company Information
  51. 7.9.2 Pfizer Business Overview
  52. 7.9.3 Pfizer Live Attenuated Measles Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Pfizer Live Attenuated Measles Vaccine Product Portfolio
  54. 7.9.5 Pfizer Recent Developments
  55. 7.10 Lanzhou Institute of Biological Products Co., Ltd
  56. 7.10.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
  57. 7.10.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
  58. 7.10.3 Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
  60. 7.10.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
  61. 7.11 Merck
  62. 7.11.1 Merck Company Information
  63. 7.11.2 Merck Business Overview
  64. 7.11.3 Merck Live Attenuated Measles Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Merck Live Attenuated Measles Vaccine Product Portfolio
  66. 7.11.5 Merck Recent Developments
  67. 7.12 Novartis
  68. 7.12.1 Novartis Company Information
  69. 7.12.2 Novartis Business Overview
  70. 7.12.3 Novartis Live Attenuated Measles Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Novartis Live Attenuated Measles Vaccine Product Portfolio
  72. 7.12.5 Novartis Recent Developments
  73. 7.13 Johnson & Johnson
  74. 7.13.1 Johnson & Johnson Company Information
  75. 7.13.2 Johnson & Johnson Business Overview
  76. 7.13.3 Johnson & Johnson Live Attenuated Measles Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Johnson & Johnson Live Attenuated Measles Vaccine Product Portfolio
  78. 7.13.5 Johnson & Johnson Recent Developments
  79. 7.14 Shanghai Institute of Biological Products Co., Ltd
  80. 7.14.1 Shanghai Institute of Biological Products Co., Ltd Company Information
  81. 7.14.2 Shanghai Institute of Biological Products Co., Ltd Business Overview
  82. 7.14.3 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
  84. 7.14.5 Shanghai Institute of Biological Products Co., Ltd Recent Developments
  85. 7.15 Wuhan Institute of Biological Products Co., Ltd
  86. 7.15.1 Wuhan Institute of Biological Products Co., Ltd Company Information
  87. 7.15.2 Wuhan Institute of Biological Products Co., Ltd Business Overview
  88. 7.15.3 Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
  90. 7.15.5 Wuhan Institute of Biological Products Co., Ltd Recent Developments
  91. 7.16 Changchun Qijian Biological Products Co., Ltd
  92. 7.16.1 Changchun Qijian Biological Products Co., Ltd Company Information
  93. 7.16.2 Changchun Qijian Biological Products Co., Ltd Business Overview
  94. 7.16.3 Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
  96. 7.16.5 Changchun Qijian Biological Products Co., Ltd Recent Developments
8 North America
  1. 8.1 North America Live Attenuated Measles Vaccine Market Size by Type
  2. 8.1.1 North America Live Attenuated Measles Vaccine Revenue by Type (2021-2032)
  3. 8.1.2 North America Live Attenuated Measles Vaccine Sales by Type (2021-2032)
  4. 8.1.3 North America Live Attenuated Measles Vaccine Price by Type (2021-2032)
  5. 8.2 North America Live Attenuated Measles Vaccine Market Size by Application
  6. 8.2.1 North America Live Attenuated Measles Vaccine Revenue by Application (2021-2032)
  7. 8.2.2 North America Live Attenuated Measles Vaccine Sales by Application (2021-2032)
  8. 8.2.3 North America Live Attenuated Measles Vaccine Price by Application (2021-2032)
  9. 8.3 North America Live Attenuated Measles Vaccine Market Size by Country
  10. 8.3.1 North America Live Attenuated Measles Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Live Attenuated Measles Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Live Attenuated Measles Vaccine Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Live Attenuated Measles Vaccine Market Size by Type
  2. 9.1.1 Europe Live Attenuated Measles Vaccine Revenue by Type (2021-2032)
  3. 9.1.2 Europe Live Attenuated Measles Vaccine Sales by Type (2021-2032)
  4. 9.1.3 Europe Live Attenuated Measles Vaccine Price by Type (2021-2032)
  5. 9.2 Europe Live Attenuated Measles Vaccine Market Size by Application
  6. 9.2.1 Europe Live Attenuated Measles Vaccine Revenue by Application (2021-2032)
  7. 9.2.2 Europe Live Attenuated Measles Vaccine Sales by Application (2021-2032)
  8. 9.2.3 Europe Live Attenuated Measles Vaccine Price by Application (2021-2032)
  9. 9.3 Europe Live Attenuated Measles Vaccine Market Size by Country
  10. 9.3.1 Europe Live Attenuated Measles Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Live Attenuated Measles Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Live Attenuated Measles Vaccine Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Live Attenuated Measles Vaccine Market Size by Type
  2. 10.1.1 China Live Attenuated Measles Vaccine Revenue by Type (2021-2032)
  3. 10.1.2 China Live Attenuated Measles Vaccine Sales by Type (2021-2032)
  4. 10.1.3 China Live Attenuated Measles Vaccine Price by Type (2021-2032)
  5. 10.2 China Live Attenuated Measles Vaccine Market Size by Application
  6. 10.2.1 China Live Attenuated Measles Vaccine Revenue by Application (2021-2032)
  7. 10.2.2 China Live Attenuated Measles Vaccine Sales by Application (2021-2032)
  8. 10.2.3 China Live Attenuated Measles Vaccine Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Live Attenuated Measles Vaccine Market Size by Type
  2. 11.1.1 Asia Live Attenuated Measles Vaccine Revenue by Type (2021-2032)
  3. 11.1.2 Asia Live Attenuated Measles Vaccine Sales by Type (2021-2032)
  4. 11.1.3 Asia Live Attenuated Measles Vaccine Price by Type (2021-2032)
  5. 11.2 Asia Live Attenuated Measles Vaccine Market Size by Application
  6. 11.2.1 Asia Live Attenuated Measles Vaccine Revenue by Application (2021-2032)
  7. 11.2.2 Asia Live Attenuated Measles Vaccine Sales by Application (2021-2032)
  8. 11.2.3 Asia Live Attenuated Measles Vaccine Price by Application (2021-2032)
  9. 11.3 Asia Live Attenuated Measles Vaccine Market Size by Country
  10. 11.3.1 Asia Live Attenuated Measles Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Live Attenuated Measles Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Live Attenuated Measles Vaccine Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Live Attenuated Measles Vaccine Market Size by Type
  2. 12.1.1 SAMEA Live Attenuated Measles Vaccine Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Live Attenuated Measles Vaccine Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Live Attenuated Measles Vaccine Price by Type (2021-2032)
  5. 12.2 SAMEA Live Attenuated Measles Vaccine Market Size by Application
  6. 12.2.1 SAMEA Live Attenuated Measles Vaccine Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Live Attenuated Measles Vaccine Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Live Attenuated Measles Vaccine Price by Application (2021-2032)
  9. 12.3 SAMEA Live Attenuated Measles Vaccine Market Size by Country
  10. 12.3.1 SAMEA Live Attenuated Measles Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Live Attenuated Measles Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Live Attenuated Measles Vaccine Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Live Attenuated Measles Vaccine Value Chain Analysis
  2. 13.1.1 Live Attenuated Measles Vaccine Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Live Attenuated Measles Vaccine Production Mode & Process
  6. 13.2 Live Attenuated Measles Vaccine Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Live Attenuated Measles Vaccine Distributors
  9. 13.2.3 Live Attenuated Measles Vaccine Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst